BIOM-18. CLINICOGENOMIC PREDICTORS FOR THE PATTERN OF FAILURE IN HIGH-GRADE GLIOMA

Abstract Background High-grade gliomas, the most common primary brain tumors, are highly lethal and treatment options remain limited. Despite advances in genomic technologies, there few molecular biomarkers to guide precision medicine for high-grade glioma. Here, we aimed identify clinicogenomic features associated with its prognosis recurrence patterns. MATERIALS/METHODS Our single-institution retrospective analysis included 182 patients diagnosed gliomas who underwent next-generation sequencing targeting 82 tumor-relevant genes. Clinicopathological status, characteristics, survival, profiles were analyzed. RESULTS At a median follow-up of 23 months (range, 2-229 months), 151 (83%) had progression or recurrences. Local distant recurrences observed 132 (72.5%) 101 (54.9%) patients, respectively. The variants TP53 (42.9%), IDH1/2 (23.1%), TERT promoter (38.5%), ATRX (13.2%), H3F3A (7.1%), SETD2 (6.0%) mutation. Regarding copy number variants, amplification EGFR (20.9%), PDGFRA (9.9%), MYCN (2.2%) loss CDKN2A/2B (49.5%), PTEN (37.9%), RB1 (17.6%), 1p19q codeletion(9.3%) aberrations. On multivariate cox regression anlalysis, (HR 6.08 95% CI 1.91-19.35, p = 0.002), mutation 0.19 0.06-0.62, =0.06) independent predictors overall relation previously established prognostic factors including age, Eastern Cooperative Oncology Group Performance Status (ECOG PS) scale, extent resection, MGMT methylation, Interestingly, 5.24 1.69-16.27, 0.004), 0.35 0.12-0.99, =0.048) failure from CONCLUSION assessment characteristics conjunction pattern glioma aids likely benefit personalized medicine. We identified mutation, as potential therapeutic implications